Omega Therapeutics - OMGA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 327.35%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.34
▼ -0.05 (-2.09%)

This chart shows the closing price for OMGA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Omega Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMGA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMGA

Analyst Price Target is $10.00
▲ +327.35% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Omega Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 327.35% upside from the last price of $2.34.

This chart shows the closing price for OMGA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Omega Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.00Low
4/1/2024Chardan CapitalLower TargetBuy ➝ Buy$12.00 ➝ $7.00Low
1/4/2024WedbushReiterated RatingOutperform ➝ Outperform$12.00Low
11/13/2023HC WainwrightBoost TargetBuy ➝ Buy$11.00 ➝ $12.00Low
11/10/2023WedbushLower TargetOutperform ➝ Outperform$19.00 ➝ $12.00Low
9/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
8/4/2023Chardan CapitalReiterated RatingBuy ➝ Buy$12.00Low
3/31/2023HC WainwrightReiterated RatingBuy$11.00N/A
3/24/2023HC WainwrightReiterated RatingBuy$11.00Low
3/10/2023JonestradingInitiated CoverageBuy$11.00Low
3/3/2023Piper SandlerBoost TargetOverweight$8.00 ➝ $10.00Low
12/8/2022HC WainwrightInitiated CoverageBuy$11.00Low
9/23/2022Chardan CapitalInitiated CoverageBuy$12.00Low
7/15/2022Piper SandlerBoost Target$7.00 ➝ $8.00Low
5/24/2022The Goldman Sachs GroupLower TargetNeutral$7.00 ➝ $4.00Low
5/23/2022Piper SandlerLower TargetOverweight$30.00 ➝ $7.00High
8/24/2021WedbushInitiated CoverageOutperform$36.00High
8/24/2021Jefferies Financial GroupInitiated CoverageBuy$30.00High
8/24/2021Piper SandlerInitiated CoverageOverweight$30.00High
8/24/2021The Goldman Sachs GroupInitiated CoverageNeutral$22.00High
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/26/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/26/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/25/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2023
  • 3 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/23/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/23/2024

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Omega Therapeutics logo
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $2.34
Low: $2.32
High: $2.54

50 Day Range

MA: $3.47
Low: $2.34
High: $4.33

52 Week Range

Now: $2.34
Low: $1.30
High: $10.09

Volume

301,198 shs

Average Volume

329,393 shs

Market Capitalization

$129.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Omega Therapeutics?

The following sell-side analysts have issued research reports on Omega Therapeutics in the last year: Chardan Capital, HC Wainwright, Piper Sandler, and Wedbush.
View the latest analyst ratings for OMGA.

What is the current price target for Omega Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Omega Therapeutics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 327.4%. Wedbush has the highest price target set, predicting OMGA will reach $12.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $7.00 for Omega Therapeutics in the next year.
View the latest price targets for OMGA.

What is the current consensus analyst rating for Omega Therapeutics?

Omega Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OMGA will outperform the market and that investors should add to their positions of Omega Therapeutics.
View the latest ratings for OMGA.

What other companies compete with Omega Therapeutics?

How do I contact Omega Therapeutics' investor relations team?

Omega Therapeutics' physical mailing address is 20 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The company's listed phone number is 617-949-4360 and its investor relations email address is [email protected]. The official website for Omega Therapeutics is www.omegatherapeutics.com. Learn More about contacing Omega Therapeutics investor relations.